Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling

Antimicrobial Agents and Chemotherapy
Rajbharan YadavCornelia B Landersdorfer

Abstract

Augmented renal clearance (ARC) in critically ill patients can result in suboptimal drug exposures and treatment failure. Combination dosage regimens accounting for ARC have never been optimized and evaluated against Pseudomonas aeruginosa by use of the hollow-fiber infection model (HFIM). Using a P. aeruginosa isolate from a critically ill patient and static-concentration time-kill experiments (SCTKs), we studied clinically relevant piperacillin and tobramycin concentrations, alone and in combinations, against two inocula (105.8 and 107.6 CFU/ml) over 72 h. We subsequently evaluated the effects of optimized piperacillin (4 g every 4 h [q4h], given as 0.5-h infusions) plus tobramycin (5 mg/kg of body weight q24h, 7 mg/kg q24h, or 10 mg/kg q48h, given as 0.5-h infusions) regimens on killing and regrowth in the HFIM, simulating a creatinine clearance of 250 ml/min. Mechanism-based modeling was performed in S-ADAPT. In SCTKs, piperacillin plus tobramycin (except combinations with 8 mg/liter tobramycin and against the low inoculum) achieved synergistic killing (≥2 log10 versus the most active monotherapy at 48 h and 72 h) and prevented regrowth. Piperacillin monotherapy (4 g q4h) in the HFIM provided 2.4-log10 initial killing follo...Continue Reading

References

Jul 1, 1991·The Journal of Antimicrobial Chemotherapy·K Sato, T Nakae
Dec 1, 1991·The Journal of Antimicrobial Chemotherapy·M Obara, T Nakae
Apr 1, 1989·Journal of Bacteriology·H MaidhofP Giesbrecht
Oct 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Sep 1, 1993·Journal of Bacteriology·J L KadurugamuwaT J Beveridge
Apr 1, 1996·Chest·S Crouch BrewerK V Leeper
Feb 1, 1997·British Journal of Clinical Pharmacology·S B DuffullE J Begg
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Jun 13, 1998·Antimicrobial Agents and Chemotherapy·L L Ioannides-DemosA J McLean
Apr 30, 2002·International Journal of Antimicrobial Agents·D Andes, W A Craig
Jan 9, 2004·Infectious Disease Clinics of North America·John Turnidge
Mar 20, 2004·Nature Reviews. Microbiology·George L Drusano
Dec 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul G AmbroseGeorge L Drusano
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·Chonghua LiDavid P Nicolau
Jul 4, 2008·Critical Care Medicine·Jason A RobertsJeffrey Lipman
Feb 25, 2009·Critical Care Medicine·Jason A Roberts, Jeffrey Lipman
Dec 3, 2009·JAMA : the Journal of the American Medical Association·Jean-Louis VincentUNKNOWN EPIC II Group of Investigators
Dec 17, 2009·Clinical Pharmacokinetics·Andrew A UdyJeffrey Lipman
May 14, 2010·The New England Journal of Medicine·Anton Y Peleg, David C Hooper
Jun 3, 2010·Antimicrobial Agents and Chemotherapy·G L DrusanoArnold Louie
Dec 15, 2010·British Journal of Clinical Pharmacology·Jean-Marie ConilSylvie Saivin
Mar 4, 2011·The AAPS Journal·Jurgen Bernd BulittaCornelia Barbara Landersdorfer
May 13, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brian T TsujiPaul G Ambrose
Jul 20, 2011·Nature Reviews. Nephrology·Andrew A UdyJeffrey Lipman
Nov 16, 2011·Antimicrobial Agents and Chemotherapy·Anthony M NicasioGeorge L Drusano
Apr 11, 2013·Antimicrobial Agents and Chemotherapy·Arnold LouieG L Drusano
Jul 17, 2013·Revista Da Sociedade Brasileira De Medicina Tropical·Denissani Aparecida Ferrari dos SantosRoberto Martinez

❮ Previous
Next ❯

Citations

Mar 27, 2019·Clinical Pharmacology and Therapeutics·Jin NiuDonald E Mager
Feb 12, 2021·Clinical Pharmacology and Therapeutics·Cornelia B Landersdorfer, Roger L Nation
May 20, 2021·Journal of Veterinary Pharmacology and Therapeutics·Kaixiang ZhouLingli Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.